CRISPR Therapeutics AG (CRSP) Deep Dive Video

CRISPR Therapeutics is exiting the “valley of death”: Casgevy’s delayed revenue conversion and a wholly-owned in vivo platform create a cash-backed setup for a potential multi-year re-rating—if execution and IP risk cooperate.